NEW YORK, Sept. 4, 2008 (GLOBE NEWSWIRE) -- All Global, a leading international healthcare data collection agency, announces the launch of its new Palliative Care Panel for marketing research. Palliative care is an emerging therapy area with specialists and healthcare professionals working in oncology, heart, lung and renal disease, HIV/AIDs, dementia and other neuro-degenerative diseases. The new panel provides unique access to more than 18,000 physicians, nurses, pharmacists and healthcare professionals in 39 countries who specialize in palliative care.
"Our new research capability gives marketing researchers, consultants and marketers access to a broad range of palliative care professionals, and enables them to gain insights on physician experience, prescribing behavior, and drug combinations, as well as pain and symptom management," said Tony Burke, Managing Director.
Panelists include oncologists, anesthesiologists, primary care physicians, pharmacists and other healthcare professionals, including physiotherapists, occupational therapists, dieticians and social workers.
The new All Global service is the result of an exclusive partnership agreement with Palliativedrugs.com, an educational website for healthcare professionals co-founded by Dr. Robert Twycross and Dr. Andrew Wilcock, international thought leaders in palliative care.
About All Global
All Global is a leading international data collection company specializing in healthcare marketing research. The Company provides online, telephone and qualitative research services worldwide, using its proprietary panel of more than 200,000 physicians and other medical professionals in the U.S. and Europe. With offices in New York, London and Barcelona, All Global offers its clients a one stop shop for all their research needs. For more, visit www.allglobal.com.
About Palliativedrugs.com
Palliativedrugs.com is an educational website for healthcare professionals. The purpose of the website is to provide essential, comprehensive and independent information for healthcare professionals about the use of drugs in palliative care. It highlights drugs given for unlicensed routes and the administration of multiple drugs by continuous subcutaneous infusion.